These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27941286)

  • 21. Genetically modulating T-cell function to target cancer.
    Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
    Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cancer Immunotherapy Using Gene Modification Technology].
    Tokunaga Y; Tamada K
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):967-973. PubMed ID: 31273158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current Cancer Immunotherapy Using Activated Lymphocytes - Do Lymphocytes Actually Recognize Cancer Cells ?].
    Yamaguchi Y; Katata Y; Okawaki M; Yamamura M; Sawaki A
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1031-5. PubMed ID: 26469157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
    Göbel C; Breitenbuecher F; Kalkavan H; Hähnel PS; Kasper S; Hoffarth S; Merches K; Schild H; Lang KS; Schuler M
    Cell Death Dis; 2014 Dec; 5(12):e1568. PubMed ID: 25501829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
    Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
    Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of genetic modification of T cells for cancer treatment.
    Dotti G; Heslop HE
    Cytotherapy; 2005; 7(3):262-72. PubMed ID: 16081353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive immunotherapy for cancer or viruses.
    Maus MV; Fraietta JA; Levine BL; Kalos M; Zhao Y; June CH
    Annu Rev Immunol; 2014; 32():189-225. PubMed ID: 24423116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
    Oh I; Oh Y; Ohmine K
    Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced T cell receptor gene therapy for cancer.
    Kieback E; Uckert W
    Expert Opin Biol Ther; 2010 May; 10(5):749-62. PubMed ID: 20201709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploiting T cell receptor genes for cancer immunotherapy.
    Xue S; Gillmore R; Downs A; Tsallios A; Holler A; Gao L; Wong V; Morris E; Stauss HJ
    Clin Exp Immunol; 2005 Feb; 139(2):167-72. PubMed ID: 15654813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular immunotherapy of cancer.
    Yang JC
    Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-receptor gene-modified T cells for treatment of glioma.
    Ikeda H; Shiku H
    Adv Exp Med Biol; 2012; 746():202-15. PubMed ID: 22639170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immune cell therapy using iPS cells].
    Yano H; Kaneko S
    Rinsho Ketsueki; 2018; 59(2):225-231. PubMed ID: 29515078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of tumor-specific T-cell therapies.
    Morris E; Hart D; Gao L; Tsallios A; Xue SA; Stauss H
    Blood Rev; 2006 Mar; 20(2):61-9. PubMed ID: 15978709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.
    Ochi T; Fujiwara H; Yasukawa M
    Expert Opin Biol Ther; 2011 Jun; 11(6):699-713. PubMed ID: 21413911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.